Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice.

[1]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[2]  A. Clark,et al.  Efficient generation of transgenic pigs using equine infectious anaemia virus (EIAV) derived vector , 2004, FEBS letters.

[3]  P. Carmeliet,et al.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.

[4]  M. Brittan,et al.  Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. , 2004, Blood.

[5]  R. Barber,et al.  Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector , 2004, Neuroreport.

[6]  David A. Williams,et al.  Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[8]  K. Cornetta,et al.  American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  C. Coutelle,et al.  Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice , 2003, Gene Therapy.

[10]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[11]  J. Olsen,et al.  Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  J. Uney,et al.  Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  B. Aronow,et al.  Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.

[14]  N. Mazarakis,et al.  New methods to titrate EIAV-based lentiviral vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[16]  L. Naldini,et al.  Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. , 2002, Human gene therapy.

[17]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[18]  A. Kingsman,et al.  Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.

[19]  J. Olsen.  Gene transfer vectors derived from equine infectious anemia virus , 1998, Gene Therapy.

[20]  G. Fourel,et al.  Woodchuck Hepatitis Virus Enhancer I and Enhancer II Are Both Involved in N-myc2 Activation in Woodchuck Liver Tumors , 1998, Journal of Virology.

[21]  M. Zoppè,et al.  A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Schirmacher,et al.  Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication , 1996, Journal of virology.

[23]  R. Costa,et al.  Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. , 1991, Nucleic acids research.

[24]  D. Forrest,et al.  Mechanisms of retrovirus-induced leukaemia: selected aspects. , 1987, Biochimica et biophysica acta.

[25]  R. Jaenisch,et al.  Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites , 1987, Journal of virology.

[26]  M. Zijlstra,et al.  Involvement of c‐myc in MuLV‐induced T cell lymphomas in mice: frequency and mechanisms of activation. , 1984, The EMBO journal.

[27]  W. S. Hayward,et al.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis , 1981, Nature.

[28]  H. Varmus,et al.  Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA , 1977, Cell.

[29]  K. Mitrophanous,et al.  Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE) , 2005, Gene Therapy.

[30]  N. Mazarakis,et al.  Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. , 2002, Methods in enzymology.